Chi-Med starts Phase III NSCLC trial of fruquintinib

Hutchison China MediTech Ltd. (LSE:HCM) said its Hutchison MediPharma Ltd. subsidiary began the Chinese Phase III FALUCA study of fruquintinib ( HMPL-013) as a third-line treatment for treat advanced non-squamous non-small cell lung cancer. The company expects top-line results in 2017.

FALUCA's primary endpoint will be overall survival (OS). The company said in September that fruquintinib met the primary endpoint of progression-free survival (PFS) in a Phase II study to treat NSCLC. ...